Navigation Links
Decoding vaccination: Mayo researchers reveal genetic underpinnings of response to measles vaccine
Date:9/22/2011

ROCHESTER, Minn. -- Researchers at Mayo Clinic are hacking the genetic code that controls the human response to disease vaccination, and they are using this new cipher to answer many of the deep-seated questions that plague vaccinology, including why patients respond so differently to identical vaccines and how to minimize the side effects to vaccination.

Led by Gregory Poland, M.D., researchers in Mayo's Vaccine Research Group are publishing results of two genetic studies that identify mutations linked to immune response to the measles vaccine. They appear in the journal Vaccine.

"We are trying to understand, to the maximum extent possible, how a person's individual genetic makeup affects response to vaccination," says Dr. Poland.

These and similar studies will likely allow physicians to prescribe appropriate doses and timing of vaccines based on routine genetic screening blood tests in the near future. Longer-reaching implications of the vaccine group's work include the development of more effective vaccines and, perhaps someday, the ability to construct personalized vaccines.

"Vaccination is the single most important and far-reaching practice in medicine. By the time a child enters school in the United States, they have received upwards of 20 shots," says Dr. Poland. "In no other field of medicine do we do exactly the same thing to everyone and we do it everywhere in the world."

Doctors and epidemiologists have long been puzzled about the genetic underpinnings to the fact that up to 10 percent of recipients fail to respond to the first dose of the measles vaccine, while another 10 percent generate extremely high levels of measles antibodies. The remaining 80 percent fall somewhere in the middle.

"We have found that two doses of the vaccine seem to be sufficient to immunize the vast majority of the population against measles, so we do it to everybody even though it's not technically necessary," says Dr. Poland. "If we could tell, based on a genetic test of every patient, who would need one dose and who might need two or three, imagine the implications not only for measles vaccines, but for every vaccine."

Millions of dollars could be saved by avoiding additional and unnecessary vaccine doses, not to mention the pain and suffering that could be spared by administering to young children the minimum number of shots necessary.

Early results published in Vaccine contain an exhaustive statistical analysis of the genes coding for the Human Leukocyte Antigen (HLA) system and other known cytokine/cytokine receptor genes. Dr. Poland's team was the first to single out all DNA base-pair mutations in these genes that have a measurable effect on the immune system's response to measles vaccination.

Any mutations found to play a role in the immune system response to the measles vaccine were identified and cataloged with the study subject's corresponding race.

Called SNPs (pronounced "snips"), these tiny genetic mutations represent the smallest possible change to a person's genetic code and offer clues to explaining why children of some racial and ethnic groups respond better to vaccination than other groups.

Ultimately, Dr. Poland and his team seek to assemble a comprehensive matrix of all the genetic mutations that affect immune response to vaccination on all of the roughly 30,000 human protein-coding genes. Such a library could direct physicians toward predicting exactly how individuals will respond to different vaccines.

"Imagine setting up an array of dominoes the size of a small city, and then depending on where you knock one over, predicting how the rest will fall," says Dr. Poland. "That is what we are trying to do in understanding how single genes, and networks of genes, control and determine our immune responses to vaccines and, hence, whether we are protected or not."


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Pediatric flu vaccination: Understanding low acceptance rates could help increase coverage
2. Swine Flu vaccination: voluntary system works
3. Researchers discover how promiscuous parasites hijack host immune cells
4. Buyer beware: Advertising may seduce your brain, UCLA researchers say
5. Researchers Find Link Between Epilepsy, Schizophrenia Risk
6. Researchers identify components that keep immune system in check
7. Researchers identify potential molecular target to prevent growth of cancer cells
8. Cleveland Clinic researchers awarded NIH grant to study concussion-identifying blood test
9. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
10. $1.1 million grant targets disparities among medical researchers
11. Yale researchers use uterine stem cells to treat diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... pharmacy industry, today announced that it was chosen as the Pharmaceutical News Provider ... Awards . The awards acknowledge the hard work and dedication of community members ...
(Date:5/4/2016)... ... May 04, 2016 , ... AudioEducator is the country's top ... months, AudioEducator has lined up some informative training session for the medical coding ... compliance know-how and practical, easy-to-apply advice. , On Thursday, May 19, AudioEducator will ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... Patient 2016, a powerful cellular therapy software application that helps blood and ... to patients. , Since Transtem’s initial launch, Mediware has continued to enhance core ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Fertility Centers ... at 535 Ocean Ave. Their new Maine Fertility Center provides convenient access to care ... Anne Rainville and her staff at Women’s Wellness Comprehensive Care in Portland,” said Fertility ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
Breaking Medicine Technology: